Previously, such chemically synthesized polypeptide products were excluded from the regulatory transition, so subsequent-entry products referencing these drugs would not be eligible for biosimilars or interchangeable product approval. Such products would also not be eligible for generic drug development.
This week, the House of Representatives approved a $1.4 trillion spending package, and included in the bill is a newly added provision, reported BioWorld, that will allow chemically synthesized polypeptides to be included in the upcoming March 2020 transition of some products to regulation as biologics and biosimilars rather than as drugs and follow-ons.
Previously, such chemically synthesized polypeptide products were excluded from the regulatory transition, so subsequent-entry products referencing these drugs would not be eligible for biosimilars or interchangeable product approval. Such products would also not be eligible for generic drug development.
In a statement, the FDA’s deputy commissioner for policy, legislation, and international affairs, Anna Abram, and director of the Center for Drug Evaluation and Research, Janet Woodcock, MD, voiced support for the change.
The previous exclusion of chemically synthesized polypeptides from the regulatory rollover, said Abram and Woodcock, “could hurt potential competition because it means that if a developer were to chemically synthesize a copy of a protein product (e.g., an insulin copy), the product would not be able to come to market through the abbreviated biosimilar or interchangeable pathway, but instead would have to submit a new drug application, which could be much more resource-intensive.”
Removing the exclusion, said the regulators, will help patients get access to cheaper drugs sooner—including chemically synthesized insulins—through a more efficient regulatory pathway. They also said that the change will allow for innovation in manufacturing processes, which could have benefits in terms of efficiency.
However, detractors note that the change could have impacts on intellectual property protections for these products, given the fact that biologics are subject to lengthier patent protection than are small-molecule products. Public Citizen, for one, said in a statement that the provision could have the result of “forcing consumers to wait years for affordable medicine.”
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.